165 related articles for article (PubMed ID: 35860593)
21. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.
Berdelou A; Borget I; Godbert Y; Nguyen T; Garcia ME; Chougnet CN; Ferru A; Buffet C; Chabre O; Huillard O; Leboulleux S; Schlumberger M
Thyroid; 2018 Jan; 28(1):72-78. PubMed ID: 29048237
[No Abstract] [Full Text] [Related]
22. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
[No Abstract] [Full Text] [Related]
25. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
26. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians.
Houron C; Danielou M; Mir O; Fromenty B; Perlemuter G; Voican CS
Crit Rev Oncol Hematol; 2021 Jan; 157():103127. PubMed ID: 33161366
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
Yoo C; Kim JH; Ryu MH; Park SR; Lee D; Kim KM; Shim JH; Lim YS; Lee HC; Lee J; Tai D; Chan SL; Ryoo BY
Liver Cancer; 2021 Apr; 10(2):107-114. PubMed ID: 33977087
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
De Leo S; Di Stefano M; Persani L; Fugazzola L; Colombo C
Endocrine; 2021 May; 72(2):462-469. PubMed ID: 32885329
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
30. Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Reed N; Glen H; Gerrard G; Good J; Lei M; Lyon AR; Strachan M; Wadsley J; Newbold K
Clin Oncol (R Coll Radiol); 2020 May; 32(5):e145-e153. PubMed ID: 31843241
[TBL] [Abstract][Full Text] [Related]
31. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
32. Nutrition in Advanced Thyroid Cancer Patients.
Agate L; Minaldi E; Basolo A; Angeli V; Jaccheri R; Santini F; Elisei R
Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334955
[TBL] [Abstract][Full Text] [Related]
33. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis.
Iwasaki H; Toda S; Murayama D; Kato S; Matsui A
Mol Clin Oncol; 2021 Feb; 14(2):28. PubMed ID: 33414909
[TBL] [Abstract][Full Text] [Related]
34. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
36. Clinically relevant drug interactions with multikinase inhibitors: a review.
Hussaarts KGAM; Veerman GDM; Jansman FGA; van Gelder T; Mathijssen RHJ; van Leeuwen RWF
Ther Adv Med Oncol; 2019; 11():1758835918818347. PubMed ID: 30643582
[TBL] [Abstract][Full Text] [Related]
37. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
38. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
Li JR; Yang CR; Cheng CL; Ho HC; Chiu KY; Su CK; Chen WM; Wang SS; Chen CS; Yang CK; Ou YC
Support Care Cancer; 2013 Mar; 21(3):907-11. PubMed ID: 23262811
[TBL] [Abstract][Full Text] [Related]
40. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
